

NEWS RELEASE

16<sup>th</sup> January 2016, Hyderabad, India

**Aurobindo Pharma receives USFDA Approval for Paricalcitol Capsules**

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Paricalcitol Capsules, 1 mcg, 2 mcg, and 4 mcg. This product is expected to be launched in Q1 FY16-17.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zemplar® capsules 1 mcg, 2 mcg and 4 mcg of ABBVIE.

Paricalcitol Capsules is used for the prevention and treatment of high levels of parathyroid hormone in certain patients with chronic kidney disease. The approved product has an estimated market size of US\$ 38 million for the twelve months ending November 2015 according to IMS.

This is the 58<sup>th</sup> ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 231 ANDA approvals (200 Final approvals including 10 from Aurolife Pharma LLC and 31 Tentative approvals) from USFDA.

**About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergies, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

**For further information, please contact:**

Investor Relations  
Phone: 040-66725401 / 66725000  
Mobile: +91 98486 67906  
Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)

**Disclaimer:**

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

**AUROBINDO PHARMA LIMITED**

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059  
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : [info@aurobindo.com](mailto:info@aurobindo.com)

[www.aurobindo.com](http://www.aurobindo.com)